Companies · Biotechnology

Cardio Diagnostics Inc.

Chicago · Biotechnology

Diligence memoA one-page analyst read on Cardio Diagnostics Inc. — recommendation, valuation, rhythm, risks.
$13.2M
Total raised · real
2
Rounds
0.6×
Latest step-up
Top 40%
Sector rank · raised
Series A
Latest stage · inferred · Mon May 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Cardio Diagnostics Inc. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.12× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
Dormant
  • Last raise 4.1 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Cardio Diagnostics Inc. is one of 4291 Biotechnology companies tracked from Chicago. By capital raised it ranks mid-pack (ahead of 61% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

medical-devices

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
47
Investors (latest)
2020
Year incorporated
2022-05-23
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeries A · 2021-04-06 Raised $6.7M (real) Modeled valuation $168M (est)$6.7M$168MSeries A2021Series A · 2021-07-01 Raised $6.7M (real) Modeled valuation $150M (est)$6.7M$150MSeries A2021Seed · 2021-07-01 Raised $1.1M (real) Modeled valuation $27M (est)$1.1M$27MSeed2021Series A · 2022-05-19 Raised $10M (real) Modeled valuation $146M (est)$10M$146MSeries A2022Series A · 2022-05-23 Raised $6.5M (real) Modeled valuation $94M (est)$6.5M$94MSeries A2022+$6.7M+$1.1M+$10M+$6.5MCumulative $31M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$6.7M · 2021
Series A extension$6.7M · 2021
Bridge · Series A-stage$1.1M · 2021smaller follow-on
Series A extension$10.0M · 2022
Series A extension$6.5M · 2022

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$94.1M
Base estimate est.
$7.1M
Conservative case
$330.6M
Upside case
$29.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $168.1M · 2021-04-062021Series A · modeled $150.0M · 2021-07-01Seed · modeled $26.8M · 2021-07-01Series A · modeled $145.8M · 2022-05-19Series A · modeled $94.1M · 2022-05-232022
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
4.1 yr
Elapsed time used
4.1 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
3 mo
Avg between rounds
$11.7M/yr
Capital velocity
5.2 yr
On record since
2021
First round
5
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.8× above median
This company$13.2M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 1.2× above median
This company$6.5M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 1.5× above median
This company$94.1M
Sector median$64.2M

Raised more than 61% of sector peers (real $). Modeled value above 58% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #53 of 303.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0M$100.0MCapital raised (log)GeoVax Labs, Inc. · Series A Raised $39.1M · modeled $217.0M (est)Cellinfinity Bio Holding Company, LLC · Series A Raised $13.2M · modeled $215.9M (est)Adient Medical, Inc. · Series A Raised $18.2M · modeled $206.8M (est)Entegrion Inc · Series A Raised $22.7M · modeled $191.3M (est)BCD Bioscience, Inc. · Series A Raised $16.4M · modeled $188.9M (est)Pragma Biosciences Inc. · Series A Raised $14.5M · modeled $186.0M (est)MicroByre, Inc. · Series A Raised $16.1M · modeled $185.7M (est)Cardiac Insight, Inc. · Series A Raised $38.1M · modeled $183.8M (est)Cardiac Implants LLC · Series A Raised $13.5M · modeled $178.2M (est)Abintus Bio, Inc. · Series A Raised $13.7M · modeled $177.2M (est)Mosaic Biosciences, Inc. · Series A Raised $14.7M · modeled $176.1M (est)Mazen Animal Health Inc. · Series A Raised $13.5M · modeled $168.8M (est)Cardio Diagnostics Inc. (this company) Raised $13.2M · modeled $94.1M (est)Cardio Diagnostics Inc.
CompanyStageRaised · realValue · estvs peer med.
GeoVax Labs, Inc.Series A$39.1M$217.0M4.90×
Cellinfinity Bio Holding Company, LLCSeries A$13.2M$215.9M4.87×
Adient Medical, Inc.Series A$18.2M$206.8M4.67×
Entegrion IncSeries A$22.7M$191.3M4.32×
BCD Bioscience, Inc.Series A$16.4M$188.9M4.27×
Pragma Biosciences Inc.Series A$14.5M$186.0M4.20×
MicroByre, Inc.Series A$16.1M$185.7M4.19×
Cardiac Insight, Inc.Series A$38.1M$183.8M4.15×
Cardiac Implants LLCSeries A$13.5M$178.2M4.02×
Abintus Bio, Inc.Series A$13.7M$177.2M4.00×
Mosaic Biosciences, Inc.Series A$14.7M$176.1M3.98×
Mazen Animal Health Inc.Series A$13.5M$168.8M3.81×
Cardio Diagnostics Inc. this companySeries A$13.2M$94.1M2.12×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$6.7M2021-04-06$30.6M$168.1M90%
Series A$6.7M2021-07-01$30.6M$150.0M90%
Seed$1.1M2021-07-01$5.3M$26.8M90%
Series A$10.0M2022-05-19$45.5M$145.8M90%
Series A$6.5M2022-05-23$29.5M$94.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$6.7M2021-04-06
    • First recorded raise — entered as Series A.
    • 27 investors on this round.
  2. Series A$6.7M2021-07-01
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 27 investors on this round.
  3. Seed$1.1M2021-07-01
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 6.4× smaller than the prior — bridge or down round.
    • 15 investors on this round.
  4. Series A$10.0M2022-05-19
    • Raised 11 mo later, in step with the ~14 mo sector norm.
    • Round 9.5× larger than the prior — scaling up.
  5. Series A$6.5M2022-05-23
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.5× smaller than the prior — bridge or down round.
    • 47 investors on this round.
Intelligence
2022 ~Q3
Modeled next raise · ~3mo cadence
$6.5M
Modeled next size est.range $6.5M$10.4M
0.6×
Last step-up
$11.7M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Warren Hosseinion3 other2021-04
Elisa Luqman2 other2021-04
Meeshanthini Dogan1 other2021-04
Robert Philibert1 other2021-04
Elisa Michael Luqman2021-07
Warren Michael Hosseinion2021-07
Registry & provenance

Cardio Diagnostics Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1898439
SEC CIK
2020
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Cardio Diagnostics Holdings, Inc.BiotechnologyPre-Seed$1.0M$5.9Mnetwork3 shared operators · same sector
Travera, LLCBiotechnologySeries A$13.3M$89.1Msame sector · same stage
Molecularmd Corp.BiotechnologySeries A$13.1M$74.8Msame sector · same stage
Avm Biotechnology, LlcBiotechnologySeries A$13.4M$109.2Msame sector · same stage
Transave IncBiotechnologySeries A$13.0M$72.3Msame sector · same stage
Jecure Therapeutics, Inc.BiotechnologySeries A$13.0M$108.5Msame sector · same stage
Nanologix IncBiotechnologySeries A$13.0M$97.0Msame sector · same stage
Refuge Biotechnologies, Inc.BiotechnologySeries A$13.0M$108.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Cardio Diagnostics Holdings, Inc.BiotechnologyPre-Seed$5.9M98%
MOST Cardio LLCBiotechnologyPre-Seed$33.1M88%
Cardio Flow, Inc.BiotechnologySeries A$2.1M88%
Cardiodx IncBiotechnologySeries C$742.4M88%
Pace Diagnostics, Inc.BiotechnologySeed$71.0M88%
Native Cardio, Inc.BiotechnologySeed$505K87%
CardioFocus, Inc.BiotechnologySeries B$351.9M87%
CardioMech ASBiotechnologySeries B$89.0M87%
Frequently asked
How much funding has Cardio Diagnostics Inc. raised?
Cardio Diagnostics Inc. has raised approximately $13.2M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Cardio Diagnostics Inc.'s estimated valuation?
Provath's modeled valuation for Cardio Diagnostics Inc. is approximately $94.1M (modeled range $7.1M–$330.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Cardio Diagnostics Inc. at?
Cardio Diagnostics Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Mon May 23.
What does Cardio Diagnostics Inc. do and where is it based?
Cardio Diagnostics Inc. operates in the Biotechnology sector, based in Chicago.
Explore related

See where Cardio Diagnostics Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Cardio Diagnostics Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.